Published in Nat Genet on September 10, 2006
The expanding universe of p53 targets. Nat Rev Cancer (2009) 3.49
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell (2007) 3.20
Transcriptional regulation by p53. Cold Spring Harb Perspect Biol (2010) 3.16
SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell (2008) 2.67
ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer (2007) 1.94
Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A (2009) 1.79
Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev (2010) 1.61
Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene (2008) 1.57
Another fork in the road--life or death decisions by the tumour suppressor p53. EMBO Rep (2013) 1.43
Lack of evidence of HPV etiology of prostate cancer following radical surgery and higher frequency of the Arg/Pro genotype in Turkish men with prostate cancer. Int Braz J Urol (2017) 1.39
Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol (2009) 1.30
Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med (2007) 1.29
Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet (2009) 1.29
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma. PLoS One (2013) 1.16
iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia. EMBO J (2011) 1.12
Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res (2010) 1.10
Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. J Biol Chem (2009) 1.09
Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med (2009) 1.06
Life or death: p53-induced apoptosis requires DNA binding cooperativity. Cell Cycle (2010) 1.05
ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells. Cell Death Differ (2013) 1.05
iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway. BMC Cancer (2010) 1.02
Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res (2009) 1.01
Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics (2012) 1.00
Cabin1 restrains p53 activity on chromatin. Nat Struct Mol Biol (2009) 0.99
Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev (2014) 0.98
The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction. Cell Rep (2016) 0.96
TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One (2013) 0.94
Decreased PM10 exposure attenuates age-related lung function decline: genetic variants in p53, p21, and CCND1 modify this effect. Environ Health Perspect (2009) 0.94
Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. Am J Transl Res (2009) 0.92
The p53 codon 72 PRO/PRO genotype may be associated with initial central visual field defects in caucasians with primary open angle glaucoma. PLoS One (2012) 0.92
The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia. Br J Cancer (2007) 0.92
p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des (2011) 0.90
Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res (2007) 0.89
Combined effects of genetic variants of the PTEN, AKT1, MDM2 and p53 genes on the risk of nasopharyngeal carcinoma. PLoS One (2014) 0.88
Helicobacter pylori and gastric cancer: Indian enigma. World J Gastroenterol (2014) 0.87
The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma risk. PLoS One (2014) 0.86
Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein. J Biol Chem (2011) 0.85
Inhibitory member of the apoptosis-stimulating proteins of the p53 family (iASPP) interacts with protein phosphatase 1 via a noncanonical binding motif. J Biol Chem (2011) 0.85
The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform. Neoplasia (2012) 0.85
Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53. Mol Neurodegener (2014) 0.85
Lysines in the tetramerization domain of p53 selectively modulate G1 arrest. Cell Cycle (2016) 0.85
A distinct response to endogenous DNA damage in the development of Nbs1-deficient cortical neurons. Cell Res (2012) 0.84
Formation of stress-specific p53 binding patterns is influenced by chromatin but not by modulation of p53 binding affinity to response elements. Nucleic Acids Res (2010) 0.84
The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol (2011) 0.84
p53 codon 72 polymorphism and recurrent pregnancy loss: a meta-analysis. J Assist Reprod Genet (2011) 0.83
Battle against cancer: an everlasting saga of p53. Int J Mol Sci (2014) 0.83
HEDGEHOG/GLI-E2F1 axis modulates iASPP expression and function and regulates melanoma cell growth. Cell Death Differ (2015) 0.81
A novel TP53 variant (rs78378222 A > C) in the polyadenylation signal is associated with increased cancer susceptibility: evidence from a meta-analysis. Oncotarget (2016) 0.81
Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer (2010) 0.81
Sphingosine 1-phosphate induces differentiation of mesoangioblasts towards smooth muscle. A role for GATA6. PLoS One (2011) 0.80
iASPP, a previously unidentified regulator of desmosomes, prevents arrhythmogenic right ventricular cardiomyopathy (ARVC)-induced sudden death. Proc Natl Acad Sci U S A (2015) 0.80
Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. J Biol Chem (2010) 0.80
Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant. Cell Death Dis (2015) 0.80
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J (2015) 0.80
Expression of pAkt affects p53 codon 72 polymorphism-based prediction of response to radiotherapy in nasopharyngeal carcinoma. Radiat Oncol (2013) 0.79
p53 codon 72 polymorphism and liver cancer susceptibility: a meta-analysis of epidemiologic studies. World J Gastroenterol (2011) 0.79
An indirect role for ASPP1 in limiting p53-dependent p21 expression and cellular senescence. EMBO J (2011) 0.79
A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity. Cell Death Dis (2015) 0.79
Association of the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis. Springerplus (2014) 0.79
Modeling gene-environment interactions in oral cavity and esophageal cancers demonstrates a role for the p53 R72P polymorphism in modulating susceptibility. Mol Carcinog (2013) 0.79
Inhibitor of apoptosis-stimulating protein of p53 (iASPP) is required for neuronal survival after axonal injury. PLoS One (2014) 0.78
Transcriptomes and shRNA suppressors in a TP53 allele-specific model of early-onset colon cancer in African Americans. Mol Cancer Res (2014) 0.78
Characterization of novel and uncharacterized p53 SNPs in the Chinese population--intron 2 SNP co-segregates with the common codon 72 polymorphism. PLoS One (2011) 0.77
Molecular adaptation of modern human populations. Int J Evol Biol (2010) 0.77
The TP53 Codon 72 Polymorphism and Risk of Sporadic Prostate Cancer among Iranian Patients. Iran J Public Health (2014) 0.77
Data integration workflow for search of disease driving genes and genetic variants. PLoS One (2011) 0.77
Effects of prostaglandin E2 on p53 mRNA transcription and p53 mutagenesis during T-cell-independent human B-cell clonal expansion. FASEB J (2013) 0.77
In vitro effect of iASPP on cell growth of oral tongue squamous cell carcinoma. Chin J Cancer Res (2014) 0.76
p53 regulation upon genotoxic stress: intricacies and complexities. Mol Cell Oncol (2014) 0.76
Caspase cleavage of iASPP potentiates its ability to inhibit p53 and NF-κB. Oncotarget (2015) 0.75
Linking polymorphic p53 response elements with gene expression in airway epithelial cells of smokers and cancer risk. Hum Genet (2014) 0.75
TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. World J Gastroenterol (2015) 0.75
Sequence variation in PPP1R13L results in a novel form of cardio-cutaneous syndrome. EMBO Mol Med (2017) 0.75
The Trp53 delta proline (Trp53ΔP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development. Mol Carcinog (2015) 0.75
ΔN-ASPP2, a novel isoform of the ASPP2 tumor suppressor, promotes cellular survival. Biochem Biophys Res Commun (2016) 0.75
Dysfunction of the MDM2/p53 axis is linked to premature aging. J Clin Invest (2017) 0.75
Selective targeting p53(WT) lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA. Oncogene (2017) 0.75
Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas. Mol Cell Endocrinol (2017) 0.75
The IGF-1R/AKT pathway determines cell fate in response to p53. Transl Cancer Res (2016) 0.75
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell (2006) 9.47
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Follicular lymphoma international prognostic index. Blood (2004) 7.20
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
Genome sequencing and analysis of the versatile cell factory Aspergillus niger CBS 513.88. Nat Biotechnol (2007) 6.21
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med (2015) 5.44
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science (2007) 5.19
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991-2010. JAMA (2012) 4.89
Improved response to disasters and outbreaks by tracking population movements with mobile phone network data: a post-earthquake geospatial study in Haiti. PLoS Med (2011) 4.38
Availability of consumer prices from US hospitals for a common surgical procedure. JAMA Intern Med (2013) 4.35
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2004) 4.05
Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science (2007) 3.92
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80
The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab (2010) 3.61
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 3.55
Imprinting on distal chromosome 7 in the placenta involves repressive histone methylation independent of DNA methylation. Nat Genet (2004) 3.47
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol (2008) 3.13
Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991-2008. JAMA (2011) 3.09
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res (2007) 3.05
The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature (2002) 3.02
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther (2006) 2.76
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst (2007) 2.65
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet (2011) 2.60
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet (2009) 2.58
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res (2008) 2.55
Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature (2007) 2.54
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53
Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2010) 2.48
The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell (2005) 2.45
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet (2003) 2.41
Impact of telemedicine intensive care unit coverage on patient outcomes: a systematic review and meta-analysis. Arch Intern Med (2011) 2.41
Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst (2002) 2.41
Phosphoinositide 3-kinase signalling--which way to target? Trends Pharmacol Sci (2003) 2.35
Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med (2010) 2.32
Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci (2003) 2.29
Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res (2006) 2.29
Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res (2009) 2.27
The ecology, genetic diversity, and phylogeny of Huaiyangshan virus in China. J Virol (2011) 2.23
Conservation of the H19 noncoding RNA and H19-IGF2 imprinting mechanism in therians. Nat Genet (2008) 2.20
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer (2005) 2.19
Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol (2005) 2.13
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13
A general relationship between disorder, aggregation and charge transport in conjugated polymers. Nat Mater (2013) 2.11
Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med (2009) 2.10
Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol (2013) 2.08
Electron-pinned defect-dipoles for high-performance colossal permittivity materials. Nat Mater (2013) 2.05
IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol (2008) 1.97
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
The p53 pathway in breast cancer. Breast Cancer Res (2002) 1.94
Vestibular loss causes hippocampal atrophy and impaired spatial memory in humans. Brain (2005) 1.92
Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem (2002) 1.91
The association between hospital obstetrical volume and maternal postpartum complications. Am J Obstet Gynecol (2012) 1.90
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell (2008) 1.90
Adaptation of nutrient supply to fetal demand in the mouse involves interaction between the Igf2 gene and placental transporter systems. Proc Natl Acad Sci U S A (2005) 1.90
ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol (2004) 1.88
Ten years of dengue drug discovery: progress and prospects. Antiviral Res (2013) 1.84
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol (2005) 1.83
Fluorescence lifetime imaging system for in vivo studies. Mol Imaging (2007) 1.83
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol (2010) 1.76